Table 1.
Patient characteristics.
| TEAM trial (N = 9,766) | BCI cohort (N = 3,544) | |
|---|---|---|
| Age at randomization, years | ||
| <50 | 331 (3%) | 88 (3%) |
| 50–59 | 3,017 (31%) | 1,057 (30%) |
| 60–69 | 3,731 (38%) | 1,350 (38%) |
| ≥70 | 2,687 (28%) | 1,049 (30%) |
| Histological grade | ||
| Well differentiated | 1,677 (19%) | 412 (12%) |
| Moderately Differentiated | 4,797 (54%) | 1,874 (54%) |
| Poorly differentiated | 2,438 (27%) | 1,197 (34%) |
| Not known | 854 | 61 |
| Tumor size | ||
| T1 | 5,691 (58%) | 1,769 (50%) |
| T2 | 3,591 (37%) | 1,597 (45%) |
| T3–T4 | 457 (5%) | 177 (5%) |
| T0/T in situ | 6 | 0 |
| Not known | 21 | 1 |
| Nodal status | ||
| N0 | 5,113 (53%) | 1,519 (43%) |
| N1 | 4,109 (42%) | 2,025 (57%) |
| N2–3 | 478 (5%) | |
| Not known | 66 | |
| ER status | ||
| Positive | 9,585 (98%) | 3,480 (98%) |
| Negative | 176 (2%) | 63 (2%) |
| Not assessed | 5 | 1 |
| PR status | ||
| Positive | 7,301 (81%) | 2,419 (79%) |
| Negative | 1,724 (19%) | 644 (21%) |
| Not assessed | 741 | 481 |
| HER2 status | ||
| Positive | 560 (13%)a | 430 (13%) |
| Negative | 3,825 (87%)a | 2,966 (87%) |
| Not assessed | 1,735a | 148 |
| Most extensive surgery | ||
| Mastectomy | 4,333 (44%) | 1,671 (47%) |
| Wide local incision | 5,423 (56%) | 1,871 (53%) |
| No resection | 3 (<1%) | 0 (0%) |
| Not known | 7 | 2 |
| Adjuvant radiotherapy | ||
| Yes | 6,697 (69%) | 2,263 (64%) |
| No | 2,976 (31%) | 1,276 (36%) |
| Not known | 93 | 5 |
| Adjuvant chemotherapy | ||
| Yes | 3,513 (36%) | 1,110 (31%) |
| No | 6,248 (64%) | 2,430 (69%) |
| Not known | 5 | 4 |
| Histology | ||
| Ductal | 3,696 (60%) | 2,667 (75%) |
| Lobular | 809 (13%) | 498 (14%) |
| Mixed | 226 (4%) | 143 (4%) |
| Mucinous | 12 (<1%) | 8 (<1%) |
| Medullary | 3 (<1%) | 2 (<1%) |
| Papillary | 6 (<1%) | 2 (<1%) |
| Tubular | 10 (<1%) | 3 (<1%) |
| Otherb | 6 (<1%) | 3 (<1%) |
| NOSc/Missing | 1,352 (22%) | 218 (6%) |
aHER2 status only available for patients in pathology sub study (n = 6,120).
bOther histological subtypes: In situ, Bifocal, Cribiform, Multifocal, Neuroendocrine.
cNot otherwise specified.